Search Results
Nov 12, 2025, 12:49 ET Independent Medical Alliance Releases Fourth Edition of the Journal of Independent Medicine
Considering the Safety of COVID-19 mRNA Vaccines in Patients with Aneuploidy (Martin J. McCaffrey)Explores how genetic anomalies may interact with mRNA vaccine mechanisms, raising new considerations for patient-specific safety.
More news about: Independent Medical Alliance
Nov 12, 2025, 09:00 ET DR. SABINE HAZAN WINS OUTSTANDING PRESENTATION AWARD FOR GROUNDBREAKING AUTISM AND MICROBIOME RESEARCH
communication This award builds on Dr. Hazan's prior recognition three years ago, when she received an award for research demonstrating that mRNA vaccines reduce Bifidobacteria levels, later connecting these findings to loss of Bifidobacteria in individuals with autism. Her latest research shows
More news about: ProgenaBiome
Nov 12, 2025, 08:03 ET Cell Surface Bio Launches VeRSa-Select™ to Deliver the Highest Quality Custom Antibodies for Validating Difficult Therapeutic Targets
Bio, we use the same state-of-the-art technologies as our parent company for therapeutic antibody discovery. These include virus-like particles and mRNA to present native antigens, and evolutionarily divergent hosts (chickens) to generate species cross-reactive antibodies against difficult targets. Our
More news about: Cell Surface Bio
Nov 11, 2025, 10:13 ET Announcing the 2026 Franklin Institute Award Laureates
luminaries such as Nikola Tesla, Marie and Pierre Curie, Orville Wright, Thomas Edison, Albert Einstein, Jane Goodall, Stephen Hawking, and, more recently, mRNA vaccine pioneers Kizzmekia Corbett, Drew Weissman, and Katalin Karikó. "The legacy of The Franklin Institute Awards recognizes
More news about: The Franklin Institute
Nov 11, 2025, 08:58 ET iLeukon Therapeutics Presents Phase I Data for ILKN421H at SITC 2025
Late-Breaking Clinical Oral Presentation Highlights Promising Safety, Efficacy, and Immune Activation Profile of ILKN421H, a Next-Generation mRNA-Based IL-2 Therapeutic for Advanced Solid Tumors SAN DIEGO,
More news about: iLeukon Therapeutics
Nov 10, 2025, 17:31 ET Oropharyngeal Cancer Market to Register Steady CAGR Throughout Forecast Period (2025-2034) Amid Shifting Treatment Paradigms | DelveInsight
particularly in HPV-associated cancers and in combination with other treatments. BioNTech's BNT113, an mRNA-based cancer immunotherapy, targets the HPV16-derived oncoproteins E6 and E7—key drivers in HPV16-positive solid tumors. In September 2024, BioNTech
More news about: DelveInsight Business Research, LLP
Nov 10, 2025, 14:40 ET INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm
Therapeutics specializes in creating mRNA vaccines and therapies. THE ALLEGED WRONGDOING: On October 22, 2025, Arcturus reported Phase 2 trial results for its inhaled mRNA therapy ARCT-032 in cystic fibrosis,
More news about: Edelson Lechtzin LLP
Nov 10, 2025, 06:39 ET Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer
following surgical resection. AK154 is Akeso's first mRNA-based therapeutic candidate to enter clinical development. This achievement marks a significant breakthrough for the company in the field of mRNA technology, following its established leadership in multi-specific antibodies,
More news about: Akeso, Inc.
Nov 10, 2025, 03:00 ET Primrose Bio Launches Prima RNApols™ ExTend Cap AU, a Next-Gen RNA Polymerase for Self-Amplifying mRNA
enables high-yield, fully capped self-amplifying mRNA with less capping reagent, template DNA and RNA polymerase. Built specifically for AU cap analogs, dsRNA reduction combined with lower reagent needs delivers higher quality, more cost-effective mRNA. Key
More news about: Primrose Bio
Nov 09, 2025, 19:00 ET Innovent and SanegeneBio Announce Phase 1 Clinical Data for IBI3016 Presented at American Heart Association (AHA) 2025 Annual Meeting
IBI3016 demonstrates sustained and potent AGT mRNA suppression with preliminary evidence of antihypertensive efficacy after single-dose subcutaneous administration. The clinical Phase 1 data of IBI3016 further support
More news about: Innovent Biologics
Nov 07, 2025, 09:00 ET CREATE Medicines Announces Positive First-in-Human Results for MT-302
Therapeutics), a biotechnology company advancing in vivo immune-cell programming with mRNA-LNP therapeutics, today announced first-in-human results from its Phase 1 MYE Symphony trial (NCT05969041) evaluating MT-302, an mRNA-LNP-encoded TROP2-targeted in vivo CAR therapy in patients with advanced solid tumors,
More news about: CREATE Medicines, Inc.
Nov 07, 2025, 09:00 ET Diakonos Oncology Presents Promising Preliminary Data from Phase 1 Study of DOC1021 Cell-Based Immunotherapy in Pancreatic Cancer at Society for Immunotherapy of Cancer 40th Annual Meeting
patient-derived double-loaded dendritic cell therapy that uniquely combines tumor lysate and amplified tumor-derived mRNA. The immunotherapy is made with a patient's dendritic cells combined with mRNA and proteins prepared from freshly obtained patient tumor specimens. The unique double-loading
More news about: Diakonos Oncology
Nov 06, 2025, 21:00 ET Argo Biopharma to Present Positive Phase I Results of siRNA Therapeutic BW-20805 for HAE at ACAAI 2025
worldwide.2 Current treatments require frequent dosing, highlighting the need for long-acting, preventive therapies. BW-20805 targets human hepatic PKK mRNA to inhibit PKK gene expression, offering the potential for effective prevention of HAE attacks with a significant and longer-lasting therapeutic effect.
More news about: Argo Biopharmaceutical Co., Ltd
Nov 05, 2025, 16:00 ET Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program
comparing its oral COVID-19 vaccine candidate against an FDA-approved mRNA COVID-19 injectable vaccine in adults previously immunized against COVID-19. The primary endpoint is the relative efficacy of Vaxart's candidate compared to the mRNA comparator for the prevention of symptomatic disease, with the primary
More news about: Dynavax Technologies
Nov 05, 2025, 08:30 ET Parker Institute for Cancer Immunotherapy Demonstrates Leadership and Showcases Latest Advances in Immunotherapy at SITC 2025 Annual Meeting
pioneering work has been critical to the development of groundbreaking cancer therapies, including Tecentriq® (atezolizumab), patient-specific neo-antigen mRNA and DNA vaccines, T cell-engaging bispecific antibodies and novel immunotherapies such as tiragolumab (anti-TIGIT). Dr. Mellman will receive the award
More news about: Parker Institute for Cancer Immunotherapy
Nov 05, 2025, 07:07 ET Nona Biosciences Announces Expansion of Collaboration with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies
antibodies as a plug-and-play system, including bispecific antibodies, multi-specific antibodies, CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more. By integrating
More news about: Nona Biosciences
Nov 04, 2025, 08:32 ET iLeukon Receives FDA Clearance of IND Application for A Phase II Study of mRNA-based non-alpha IL-2 variant, ILKN421H, in Advanced Non-Small Cell Lung Cancer (NSCLC)
NSCLC. ILKN421H is a novel LNP-formulated mRNA therapy encoding a non-alpha HSA–IL-2v fusion protein for the treatment of cancer. Administered intravenously every three weeks, ILKN421H achieves efficient and preferential mRNA expression in lymphoid organs with an extended half-life of
More news about: iLeukon Therapeutics
Nov 04, 2025, 08:15 ET Grit Biotherapeutics Invited to Deliver Oral Presentation at ASH 2025 on Breakthrough In Vivo CAR-T Therapy GT801
The abstract, titled "Precision In Vivo CAR-T Generation via CLAMP-Enabled mRNA Delivery: Toward Scalable and Translatable Cell Therapy," was accepted in the CAR-T Cell Therapies: Basic and Translational session. The presentation
More news about: Grit Biotherapeutics Co., Ltd.
Nov 04, 2025, 07:00 ET Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment
said John C. Jacobs, President and Chief Executive Officer, Novavax. "We look forward to Sanofi's success in globally marketing our protein-based, non-mRNA COVID-19 vaccine in the years to come." Novavax is eligible to receive additional future milestones and royalties under the CLA
More news about: Novavax, Inc.
Nov 03, 2025, 09:01 ET Orna Therapeutics Announces Multiple Presentations Supporting its in vivo CAR Programs for Autoimmune Diseases at the 67th American Society of Hematology Annual Meeting
therapeutics to unlock the potential of RNA medicine to treat diseases anywhere in the body. Orna's oRNA transcripts have advantages over traditional mRNA approaches, including simplified production, improved formulation into lipid nanoparticles, and superior protein expression. Its industry-leading LNP-based
More news about: Orna Therapeutics
Nov 03, 2025, 08:00 ET CREATE Medicines to Present Late-Breaking Clinical Data on MT-302 at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
of traditional cell therapy." MT-302 is an investigational mRNA-LNP in vivo CAR therapy designed to elicit an adaptive immune response against solid tumors. Delivered systemically using CREATE's mRNA-LNP platform, MT-302 programs the immune system to recognize and eliminate TROP2-expressing
More news about: CREATE Medicines, Inc.
Nov 03, 2025, 07:00 ET Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO
cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes,
More news about: Samsung Biologics
Nov 01, 2025, 08:00 ET Semaglutida entra para o "hall da fama" da revista Time como uma das melhores invenções dos últimos 25 anos
obesidade e doenças crônicas graves, acaba de ser incluída pela revista TIME na lista das invenções mais icônicas dos últimos 25 anos — ao lado da vacina de mRNA contra COVID-19, do iPhone e do YouTube. A molécula ganhou popularidade ao ter sua efetividade comprovada no tratamento da obesidade
More news about: NOVO NORDISK
Oct 31, 2025, 07:49 ET AbbVie Reports Third-Quarter 2025 Financial Results
anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases as well as a proprietary tLNP platform designed to deliver RNA payloads, such as mRNA, capable of engineering specific cell types in vivo. AbbVie announced that it submitted a New Drug Application (NDA)
More news about: AbbVie
Oct 30, 2025, 16:54 ET BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M
preclinical supply of DPX+peanut antigen for the peanut allergy vaccine program, and additional proof of concept studies for expanding the DPX formulations in mRNA and neoantigens; (3) initiating DPX food allergy program at McMaster University for conducting a preclinical proof of concept study with a DPX peanut
More news about: BioVaxys Technology Corp.